JHY

Across TCGA pan-cancer cohorts, JHY Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated JHY data layer compared with 23 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher JHY Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated JHY expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

THYM, UCEC, and OV are the cancer types where JHY Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	All	0.847	0.623	.002	32	view →
OV	DFS	Median	II,III,IV	0.228	0.542	.011	18	view →
SCLC	DFS	Median	II,III,IV	1.000	0.298	.022	7	view →
LGG	OS	Median	All	0.204	0.799	<.001	6	view →
LIHC	OS	Median	All	0.223	0.708	.010	6	view →
BRCA	DFS	Median	II,III,IV	0.790	0.942	.029	4	view →
SKCM	OS	Median	All	0.168	0.329	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

JHY–THYM (OS)

Open the THYM breakdown →